Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuldeep Singh Sachdeva

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Plos One|February 7, 2015
Catching the missing million: experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in IndiaNeeraj Raizada, Kuldeep Singh Sachdeva, Achuthan Sreenivas, et al.
Plos One|September 8, 2017
Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysisSunil Khaparde, Neeraj Raizada, Sreenivas Achuthan Nair, et al.
International Journal of Mycobacteriology|December 4, 2019
Insights in tuberculosis immunology: Role of NKT and T regulatory cellsPooja Pandey, Anuj Kumar Bhatnagar, Anant Mohan, et al.
Tropical Medicine and Infectious Disease|January 22, 2024
Test and Treat Model for Tuberculosis Preventive Treatment among Household Contacts of Pulmonary Tuberculosis Patients in Selected Districts of Maharashtra: A Mixed-Methods Study on Care Cascade, Timeliness, and Early Implementation ChallengesPalak Mahajan, Kathirvel Soundappan, Neeta Singla, et al.
Plos One|February 27, 2016
Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective AnalysisSreenivas Achuthan Nair, Neeraj Raizada, Kuldeep Singh Sachdeva, et al.
Plos One|August 25, 2015
Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in IndiaRajesh D Deshmukh, D J Dhande, Kuldeep Singh Sachdeva, et al.
BMC Health Services Research|August 7, 2024
Assessing the impact of COVID-19 management on the workload of human resources working in India's National Tuberculosis Elimination ProgramChristina Mergenthaler, Aarushi Bhatnagar, Di Dong, et al.
Plos One|July 2, 2015
The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant TuberculosisKuldeep Singh Sachdeva, Neeraj Raizada, Radhey Shyam Gupta, et al.
Plos One|November 11, 2011
Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, IndiaSarabjit S Chadha, B N Sharath, Kishore Reddy, et al.
Plos One|August 5, 2011
Source of previous treatment for re-treatment TB cases registered under the National TB control Programme, India, 2010Kuldeep Singh Sachdeva, Srinath Satyanarayana, Puneet Kumar Dewan, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Plos One|February 7, 2015
Catching the missing million: experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in IndiaNeeraj Raizada, Kuldeep Singh Sachdeva, Achuthan Sreenivas, et al.
Plos One|September 8, 2017
Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysisSunil Khaparde, Neeraj Raizada, Sreenivas Achuthan Nair, et al.
International Journal of Mycobacteriology|December 4, 2019
Insights in tuberculosis immunology: Role of NKT and T regulatory cellsPooja Pandey, Anuj Kumar Bhatnagar, Anant Mohan, et al.
Tropical Medicine and Infectious Disease|January 22, 2024
Test and Treat Model for Tuberculosis Preventive Treatment among Household Contacts of Pulmonary Tuberculosis Patients in Selected Districts of Maharashtra: A Mixed-Methods Study on Care Cascade, Timeliness, and Early Implementation ChallengesPalak Mahajan, Kathirvel Soundappan, Neeta Singla, et al.
Plos One|February 27, 2016
Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective AnalysisSreenivas Achuthan Nair, Neeraj Raizada, Kuldeep Singh Sachdeva, et al.
Plos One|August 25, 2015
Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in IndiaRajesh D Deshmukh, D J Dhande, Kuldeep Singh Sachdeva, et al.
BMC Health Services Research|August 7, 2024
Assessing the impact of COVID-19 management on the workload of human resources working in India's National Tuberculosis Elimination ProgramChristina Mergenthaler, Aarushi Bhatnagar, Di Dong, et al.
Plos One|July 2, 2015
The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant TuberculosisKuldeep Singh Sachdeva, Neeraj Raizada, Radhey Shyam Gupta, et al.
Plos One|November 11, 2011
Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, IndiaSarabjit S Chadha, B N Sharath, Kishore Reddy, et al.
Plos One|August 5, 2011
Source of previous treatment for re-treatment TB cases registered under the National TB control Programme, India, 2010Kuldeep Singh Sachdeva, Srinath Satyanarayana, Puneet Kumar Dewan, et al.
Pageof 5